AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects

AIMS: AJM300 is an oral antagonist of α4‐integrin that reduces inflammation by blocking leucocyte trafficking. This study aimed to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of AJM300 in healthy male subjects. METHODS: A total of 23 subjects were randomised to receive 24...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukase, Hiroyuki, Kajioka, Toshifumi, Oikawa, Ichiro, Ikeda, Naoki, Furuie, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080631/
https://www.ncbi.nlm.nih.gov/pubmed/31658381
http://dx.doi.org/10.1111/bcp.14151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080631/
https://www.ncbi.nlm.nih.gov/pubmed/31658381
http://dx.doi.org/10.1111/bcp.14151

Ejemplares similares